annb0t
Top 20
Immutep Limited
Achievement Allows IND-enabling Studies in 1Hâ2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases
Media Release
SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been esta...
>>> Read more: Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
Achievement Allows IND-enabling Studies in 1Hâ2023 and Subsequent Clinical Testing of IMP761 to Address Root Cause of Autoimmune Diseases
Media Release
SYDNEY, AUSTRALIA, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been esta...
>>> Read more: Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
